Among early tumor stage lesions (0, I, II; n = 1279), 45% were c-Met+ (n = 573), contrary to 59% of c-Met+ (n = 74) at tumor late stage lesions (III, IV; n = 124). This evidence concerns the gene MET and neoplasm.